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Summary
Background New technologies have enabled the potential for stratified medicine in
psoriasis. It is important to understand patients’ preferences to enable the
informed introduction of stratified medicine, which is likely to involve a number
of individual tests that could be collated into a prescribing algorithm for biologi-
cal drug selection to be used in clinical practice.
Objectives To quantify patient preferences for an algorithm-based approach to pre-
scribing biologics (‘biologic calculator’) in psoriasis.
Methods An online survey comprising a discrete choice experiment (DCE) was
conducted to elicit the preferences of two purposive samples of adults living with
psoriasis in the UK, identified from a psoriasis patient organization (Psoriasis
Association) and an online panel provider (Dynata). Respondents chose between
two biologic calculators and conventional prescribing described using five attri-
butes: treatment delay; positive predictive value; negative predictive value; risk of
infection; and cost saving to the National Health Service. Each participant selected
their preferred alternative from six hypothetical choice sets. Additional data,
including sociodemographic characteristics, were collected. Choice data were
analysed using conditional logit and fully correlated random parameters logit
models.
Results Data from 212 respondents (67 from the Psoriasis Association and 145
from Dynata) were analysed. The signs of all estimated coefficients were consis-
tent with a priori expectations. Respondents had a strong preference for a high
predictive accuracy and avoiding serious infection, but there was evidence of sys-
tematic differences in preferences between the samples.
Conclusions This study indicates that individuals with psoriasis would value a bio-
logic calculator and suggested that such a biologic calculator should have suffi-
cient accuracy to predict future response and risk of serious infection from the
biologic.
What is already known about the topic?
• Factors such as patient characteristics, location of psoriasis and genetics have been
found to affect response to targeted biological therapy in people with psoriasis.
• The knowledge of such factors paves the way for algorithm-based prescribing
(stratified medicine).
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What does this study add?
• We investigated patient preferences for a hypothetical example of algorithm-based
prescribing of biologics for psoriasis vs. the conventional approach to prescribing.
• The strongest predictors of patient preferences for stratified medicine were the abil-
ity to predict nonresponse to a biologic, the ability to predict a positive response
and the risk of avoiding a serious infection from the biologic.
What are the clinical implications of this work?
• This study suggests that clinical tools to enable the implementation of stratified
medicine in psoriasis should be designed with the goal of reaching a sufficient
level of predictive accuracy and predicting the risk of serious infection given the
cost of implementing these into clinical practice.
Targeted biological therapies (‘biologics’) are a highly effec-
tive addition to systemic treatments available for moderate-to-
severe psoriasis.1 However, the use of biologics may be linked
to adverse events (AEs) such as injection site reactions and
infections (tuberculosis, lower respiratory tract, and skin and
soft tissue).2–4 Not all patients will respond to the selected
biologic, and secondary failure complicates treatment in an
important subset. Given that biologics are expensive and
delays in achieving effective treatment are undesirable, there is
a sizeable interest in the development of tools to help inform
clinicians about targeted treatment selection (stratified medi-
cine).
Ongoing programmes of work seek to develop ‘stratified
medicine’ approaches to the prescribing of biologics with the
objective of enabling cost and time savings through improved
response rates and a decreased probability of AEs.5,6 There
have been significant advances in recent years, suggesting that
targeted biologic selection may be feasible in psoriasis through
therapeutic drug monitoring and, potentially, by genomic test-
ing.7,8 The information from the results of these individual
assessments and patient characteristics could be collated into a
prescribing algorithm (hereafter termed ‘biologic calculator’)
to aid clinicians’ and patients’ decision-making when choosing
an appropriate biologic. Using such a biologic calculator
would, in theory, result in a more efficient use of healthcare
resources and enhanced quality of life for people with psoria-
sis.
Prescribing algorithms, in general, and a biologic calculator,
specifically, may be characterized by their ability to predict
accurately who will [positive predictive value (PPV)] or will
not [negative predictive value (NPV)] safely respond. It is pos-
sible to improve the predictive value of a prescribing algo-
rithm by including specific variables [such as body mass
index, smoking status, sex and location of psoriasis,7 as well
as relevant biomarkers (e.g. HLA-C*06:02 genotype status)].5
The introduction of such variables may delay treatment initia-
tion and increase financial burden owing to additional tests,
such as those to determine genotype status. When determining
the required predictive values of a prescribing algorithm,
researchers developing a biologic calculator must weigh the
incremental benefit gained from additional information against
the incremental cost of collecting it.
Discrete choice experiments (DCEs) are a potentially useful
method to use to understand the benefits, harms and risks
associated with new interventions such as a prescribing algo-
rithm.9 Published studies have used DCEs to quantify patient
preferences for biologics in psoriasis; however, to our knowl-
edge, preferences for an algorithm-based approach to the pre-
scribing of these biologics have not been quantified.10,11
Including predictive (positive and negative) values as an attri-
bute in a DCE can provide information on the required level
of predictive (NPV and/or PPV) accuracy for a biologic calcu-
lator to be deemed sufficiently acceptable to inform prescrib-
ing. Such evidence could help those involved in the
development of stratified medicine approaches to guide the
informed introduction into clinical practice. This study aimed
to quantify the preferences of people with psoriasis for a ‘bio-
logic calculator’ to aid selection of a first-line biologic.
Materials and methods
A DCE to elicit the preferences of a sample of people with
psoriasis for a biologic calculator compared with the conven-
tional prescribing approach to select a biologic was embed-
ded in an online survey. Survey respondents were asked to
choose between two algorithm-based approaches (biologic
calculators A and B) and an opt-out alternative of ‘conven-
tional prescribing’ (Figure 1). The opt-out was phrased to
represent current prescribing without an algorithm. The
algorithm-based approach was framed as representing predic-
tive information in addition to current clinician-informed
prescribing. Ethical approval was obtained from the Univer-
sity of Manchester’s Research Ethics Committee (reference:
2016-0172-470).
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Survey design
The DCE was designed and analysed in line with published rec-
ommendations.12,13 The survey was programmed for online
administration using SSI Web 83.8 Sawtooth software.14 This
survey was developed parallel to, and shared many design fea-
tures with, a version for people with rheumatoid arthritis
(RA).15 The final survey version for people with psoriasis
(Appendix S1; see Supporting Information) comprised three
sections: training materials to help the respondents understand
the rationale behind the survey; the choice questions; and ques-
tions asking the respondents about themselves.
Designing the discrete choice experiment
Five attributes and relevant levels (see Table 1) were
selected to address the choice question: ‘If these were the
only approaches to prescribing biologics, which, if any,
would you choose?’ An iterative process, conducted along-
side developing a similar survey for people with RA, identi-
fied the relevant attributes.15 The results from interviews
conducted as part of a qualitative study in RA16 and five
focus groups (attended by a total of 51 individuals with
RA) were supplemented with a psoriasis support group
meeting (seven individuals), literature review of psoriasis
and DCEs, and two clinical expert interviews to inform the
selection of attributes and to ensure that participants under-
stood the survey. The psoriasis support group meeting
involved collating views of the online survey by presenting
and discussing the training materials and the framing of the
attributes and levels. The findings from the psoriasis group
meeting were consistent with those from the RA group
meetings.
Figure 1 Example choice question. NHS, National Health Service
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Four levels were assigned to each of these five attributes
(Table 1) and identified through a review of the literature,
and consultation with two clinical experts, to establish plausi-
ble and clinically relevant ranges. Appendix S2 (see Supporting
Information) describes the levels attached to each attribute and
the rationale for their selection.17–21
Experimental design
It was not possible to present all potential scenarios for a DCE
using five attributes, each with four levels (45 9 (45 – 1) /
2 = 523 776) and a main-effects fractional factorial design
was used. This approach selected a subset of scenarios that
were identified by generating an experimental design to mini-
mize the D-error using Ngene software.22 Pilot work informed
the optimal number of choice sets. The final experimental
design consisted of four blocks of five choice sets. An addi-
tional choice set was included as a ‘dominance check’ ques-
tion, in which the levels were set to suggest an ‘obvious’ best
option, to check that respondents were answering in line with
economic theory. Each respondent was therefore asked to
complete six choice sets, but only data from five of them were
used in the analysis.
Piloting
The DCE survey went through an extensive piloting process
(pilot survey with 82 patients; consultation with two academic
dermatologists) that was run in parallel with a similar survey
designed for people with RA.15 Changes were made to the
levels and their associated images for ‘cost saving to the
National Health Service (NHS)’ based on the results from the
quantitative pilot.
Training materials
Training materials were used at the start of the survey to pro-
vide respondents with sufficient information required to make
choices in the DCE.15 Bespoke training materials (see https://
mindbytes.be/our-work/patient-preference-survey-psoriasis/)
were created using a narrative storyline in collaboration with
MindBytes©,23 because this study required respondents to
become familiar with complex attributes for a biologic calcu-
lator described in terms of predictive values (NPV and PPV),
infection risk and potential cost saving to the NHS. Respon-
dents were asked to indicate if anything was unclear after
being shown the narrative storyline by answering a specific
question about whether they understood the information pro-
vided.
Background questions
To be able to describe the sample, respondents were asked to
complete key sociodemographic questions, including age, sex,
employment status, psoriasis history (time since diagnosis and
experience of biologics), a self-reported generic measure of
health status (EQ-5D-5L)24 and a disease-specific measure
[Dermatology Life Quality Index (DLQI)].25 Their responses
to the EQ-5D-5L questionnaire were valued using a published
UK-specific set of preference weights where the resulting
score is anchored on zero (representing being dead) and 1
(representing full health) with the possibility of scores below
zero (equivalent to worse than being dead) for serious health
conditions.26
Study population and sample
Individuals with psoriasis, aged 18 years or older, were
recruited from two sampling frames: a UK patient organiza-
tion for people with psoriasis (the Psoriasis Association)27 and
an online panel provider [Dynata (previously known as
ResearchNow)].28 Respondents were sent a link to the online
survey (no reminders were issued). The first question was a
screening question used to exclude those who did not have a
diagnosis of psoriasis. No restrictions were placed on the date
of diagnosis, disease severity or treatment experiences for
patients to be eligible.
Data analysis
A prespecified analysis plan was created at the design stage of
the DCE, which stated that respondents who did not com-
plete the survey, failed the dominance check question or
always chose either biologic calculator A or B in all choice
sets would be excluded. The dominance check question is a
‘test’ question that is used to verify whether the respondents
are engaging with the questions and/or understand the
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questions.29 The ‘correct’ answer to the dominance check
question should be obvious to the respondent. The decision
to exclude those who failed the dominance check question
was taken because this question had quantitative attributes
with levels that showed a logical direction of impact. There-
fore, if a respondent failed the dominance check question
with an obvious direction of preferences then they were
clearly not engaging with the survey. Descriptive statistics
were produced for respondents who were included in the
final sample.
In the base case analysis all attributes were specified as lin-
ear, continuous variables and the choice data were analysed
using conditional logit models for each sample.30 Tests for
nonlinear preferences for each attribute were conducted by
effects coding the attribute levels and comparing the model fit
using Bayesian Information Criterion across the model con-
taining the effects-coded variables and the base case model. A
Swait and Louviere plot was created (Appendix S3; see Sup-
porting Information) to identify potential differences in scale
between samples (scale heterogeneity) and true differences in
preferences (preference heterogeneity).31 The analysis plan
specified that, if there were evidence of heterogeneity (scale
or preference), a fully correlated random parameters logit
(RPL) model would be used for each sample to account for it
and allow for variation in preference parameters across indi-
vidual respondents (Appendix S3).32,33 All analyses were per-
formed using Stata 140 (StataCorp, College Station, TX,
USA).34
Balancing benefits and harms
The observed balance between the specified benefits (im-
proved predictive value) and harms (delay to treatment and
risk of serious infection) was quantified by generating esti-
mates of marginal rates of substitution (MRS) and their associ-
ated 95% confidence intervals (CIs) using the delta method.35
The MRS corresponds to the amount of an attribute respon-
dents were willing to accept in exchange for higher levels of
another attribute (see Supplementary Material S4 for additional
information).
Results
A purposive sample (comprising both sexes and a mix of age
groups) of 250 people with psoriasis completed the survey. A
final sample size of 212 respondents was available for analysis
after those who failed the dominance check question were
excluded (n = 33; three of whom originated from the patient
organization sample) and those who always chose either bio-
logic calculator A or biologic calculator B in every choice set
(n = 7). Of those who failed the dominance check question,
only one respondent did not have any formal qualifications,
which implied that failure of the dominance check was not









Male 44 (66) 68 (469) 112 (528)
Age group (years)
< 18 0 (0) 0 (00) 0 (00)
18–24 1 (1) 7 (48) 8 (38)
25–34 3 (5) 17 (117) 20 (94)
35–44 9 (13) 24 (166) 33 (156)
45–54 15 (22) 26 (179) 41 (193)
55–64 18 (27) 41 (283) 59 (278)
≥ 65 21 (31) 30 (207) 51 (241)
Occupational status
Employed full-time 28 (42) 51 (352) 79 (373)
Employed part-time 4 (6) 12 (83) 16 (76)
Self-employed 2 (3) 16 (110) 18 (85)
Unemployed 2 (3) 7 (48) 9 (43)
Retired 26 (39) 39 (269) 65 (307)
Looking after
home/family
0 (0) 7 (48) 7 (33)
Student 0 (0) 4 (28) 4 (19)
Freelance/temping 1 (1) 0 (00) 1 (05)
Long-term sickness 4 (6) 9 (62) 13 (61)
Temporarily laid off 0 (0) 0 (00) 0 (00)
Religion
No religion 35 (52) 68 (469) 103 (486)
Christian 30 (45) 65 (448) 95 (448)
Buddhist 1 (1) 3 (21) 4 (19)
Jewish 1 (1) 4 (28) 5 (24)
Hindu 0 (0) 0 (00) 0 (00)
Muslim 0 (0) 2 (14) 2 (09)
Sikh 0 (0) 1 (07) 1 (05)
Other 0 (0) 2 (14) 2 (09)
Highest level of education obtained
No formal
qualifications
0 (0) 10 (69) 10 (47)
1–4 O-levels/GCSEs 6 (9) 16 (110) 22 (104)
≥ 5 O-levels/GCSEs 5 (7) 11 (76) 16 (76)
NVQs 1 (1) 8 (55) 9 (43)
A-levels/AS-levels 10 (15) 24 (166) 34 (160)
Undergraduate
degree
21 (31) 49 (338) 70 (330)
Master’s degree 17 (25) 15 (103) 32 (151)
PhD 3 (4) 4 (28) 7 (33)
Other formal
qualification
4 (6) 8 (55) 12 (57)
Ethnicity
White British/Irish 63 (94) 126 (869) 189 (891)
White other 3 (4) 7 (48) 10 (47)
Mixed 0 (0) 3 (21) 3 (14)
Black/Black British 0 (0) 3 (21) 3 (14)
Asian/Asian British 1 (1) 4 (28) 5 (24)
Other 0 (0) 1 (07) 1 (05)
Missing 0 (0) 1 (07) 1 (05)
Data are presented as n (%). GCSE, General Certificate of Second-
ary Education; NVQ, National Vocational Qualification.
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related to lower educational attainment in this sample. The
study results were based on a final sample size of 145 respon-
dents from the online panel provider and 67 respondents from
the patient organization.
Descriptive statistics for sample characteristics for all respon-
dents and the two subsamples are reported in Table 2. On
average, people from the patient organization were more
likely to be male, > 45 years of age, in full-time employment
or retired, and a greater proportion possessed a Master’s
degree or PhD. There were also observed differences in self-
reported health status (Appendix S5; see Supporting Informa-
tion) between respondents recruited via the patient organiza-
tion, who tended to have a higher level of health status
according to the EQ-5D (mean utility score 0844), and those
identified from the online panel provider (mean utility score
0792). These values were lower than the reported mean
health status score of 0856 for the UK general population.36
The mean DLQI for both samples suggested that psoriasis had
a moderate effect on respondents’ lives. The DLQI potential
scores range from 1 (small effect on the patient’s life) to 30
(a large effect on the patient’s life). The online panel provider
sample reported a slightly greater impact of living with psoria-
sis (mean DLQI 712) vs. the patient organization sample
(mean DLQI 703). When asked if anything was unclear in
the narrative storyline, the majority of respondents (94% of
the online panel provider sample and 96% of the patient orga-
nization sample) indicated that they understood the informa-
tion provided.
Sample-reported experience of psoriasis and biologics indi-
cated that those in the online panel provider group were more
likely to have received their diagnosis in the past 5 years and
reported more recent flare-ups than those from the patient
organization (see Table 3). The vast majority of respondents
in either group had never been prescribed biologics.
Patient preferences
The results from the conditional logit models for each sample
and the Swait and Louviere plot confirmed the presence of
potential scale and preference heterogeneity (Appendix S3).31
Therefore, a fully correlated RPL model was used to estimate
parameters of the distribution of individual preferences for
each sample while adjusting for differences in scale and pref-
erences within the sample. The signs of all estimated coeffi-
cients were consistent with a priori expectations about the
direction of the effect of an attribute on preferences. A higher
amount of NPV, PPV and cost saving were preferred as
denoted by the positive signs on these coefficients, whereas a
lower amount of delay and risk were preferred as implied by
their negative coefficients.
All estimated attribute coefficients, except NPV and cost
saving, were statistically significant (P < 001) predictors of
choice in the overall sample, indicating that respondents con-
sidered most attributes while making their choices. In the
sample collected from the patient organization, all coefficients
except cost saving (P = 0056) and NPV (P = 0102) were
statistically significant at the < 005 level, meaning that for
participants in this group cost saving to the NHS and nega-
tive predictive ability (the ability to predict who will not
respond) were not statistically significant predictors of the
observed choices. In the sample collected from the online
panel provider, all estimated coefficients were statistically sig-
nificant at the < 005 level, suggesting that respondents in







Time since diagnosis of psoriasis
< 1 month 1 (1) 0 (00)
> 1 month but < 3 months 0 (0) 6 (41)
> 3 months but < 6 months 0 (0) 0 (00)
> 6 months but < 1 year 0 (0) 7 (48)
> 1 year but < 2 years 0 (0) 7 (48)
> 2 years but < 5 years 4 (6) 14 (97)
> 5 years but < 10 years 6 (9) 24 (166)
> 10 years 56 (84) 87 (600)
Time taken from formal diagnosis to initiating an effective
treatment
It happened immediately 3 (4) 20 (138)
< 1 month 9 (13) 29 (200)
> 1 month but < 3 months 7 (10) 14 (97)
> 3 months but < 6 months 6 (9) 17 (117)
> 6 months but < 1 year 4 (6) 10 (69)
> 1 year but < 2 years 7 (10) 5 (35)
> 2 years but < 5 years 5 (7) 8 (55)
> 5 years 13 (19) 16 (110)
Still not on effective treatment 13 (19) 26 (179)
Last flare-up since the diagnosis of psoriasis
I am having a flare-up now 12 (18) 30 (207)
In the last month 8 (12) 27 (186)
In the last 3 months 4 (6) 16 (110)
In the last 6 months 6 (9) 17 (117)
In the last year 10 (15) 18 (124)
> 1 year ago 21 (31) 24 (166)
I have not had a flare-up 6 (9) 13 (90)
Currently on original treatment
Yes 9 (13) 49 (338)
Yes but on a different dosage 1 (1) 12 (83)
No 57 (85) 84 (579)
Previous experience with biologics
Adalimumab (Humira) 6 (9) 7 (48)
Etanercept (Enbrel) 6 (9) 4 (28)
Infliximab (Remicade) 0 (0) 10 (69)
Ustekinumab (Stelara) 4 (6) 5 (35)
Secukinumab (Cosentyx) 2 (3) 4 (28)
Other biologic 1 (1) 4 (28)
I have not been
prescribed biologics
56 (84) 112 (772)
Not sure 0 (0) 11 (76)
Side-effects from psoriasis treatment
Yes 36 (54) 21 (145)
No 29 (43) 117 (807)
Don’t know 2 (3) 7 (48)
Data are presented as n (%).
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this group considered all attributes when making a choice.
PPV and risk were statistically highly significant (P < 0001)
in this sample. The negative and statistically significant term
for alternative-specific constant (ASC) in the online panel
provider sample indicated that respondents in this sample
preferred the biologic calculator to conventional prescribing
when attribute levels were set to be the same for all alterna-
tives. The negative ASC term for the patient organization
sample failed to reach statistical significance, meaning that
these respondents did not have a strong preference for either
of the alternatives when attribute levels were set to be the
same (Table 4).
Balancing benefits and harms
The MRS were calculated using ‘delay to treatment’ (see
Table 5) as the denominator because this attribute appeared
to be the closest to a linear functional form (Appendix S4;
see Supporting Information). Respondents collated from the
patient organization were willing to delay the start of treat-
ment by 325 days (statistically significant) and those from
the online panel provider by 389 days (statistically signifi-
cant) for a £100 cost saving. The most valued attribute in
both samples was the ability of the biologic calculator to
determine who will not respond to treatment (NPV), as both
groups were willing to wait 23–29 days for a 10% increase.
Respondents collated from the online panel provider were
willing to delay treatment by 2295 days vs. 2884 days in
the patient organization sample for an increase of 10% in
NPV, but this was not statistically significant in either group.
Another important attribute in both samples was the ability
of the biologic calculator to determine who will respond to
treatment (PPV), as respondents from the patient organiza-
tion were willing to delay treatment by 1922 days and
those from the online panel provider by 1409 days (statisti-
cally significant in both groups). The patient organization
group of respondents displayed stronger preferences for pre-
dictive accuracy of the algorithm. The MRS values for the
ability to predict response (PPV) and nonresponse (NPV)
were not statistically different from one another in either of
the samples.
Discussion
This study was designed to quantify the preferences of indi-
viduals with psoriasis for an algorithm-based approach to pre-
scribing biologics. All five attributes (NPV, PPV, risk of
serious infection, delay to treatment and cost saving to the
NHS) were consistent with a priori expectations in terms of
the direction and magnitude of the estimated coefficients.







ASC (none) –2409 (1034) –18777 (685)** –6253 (248)*
Delay –0094 (004)* –0031 (001)** –0028 (001)**
PPVb 1807 (059)** 0432 (007)*** 0425 (006)***
NPVb 2712 (166) 0704 (031)* 0155 (034)
Risk –0679 (029)* –0323 (007)*** –0217 (006)***
Costc 0306 (016) 0119 (004)** 0067 (004)
Number of observations 1005 2175 3180
ASC, alternative-specific constant; BIC, Bayesian Information Criterion; NPV, negative predictive value (ability to predict nonresponse); PPV,
positive predictive value (ability to predict response); SE, standard error. aThe BIC for the patient organization sample suggested that the ran-
dom parameters logit [random parameters logit (RPL)] model does not provide sufficient explanatory power given the number of additional
parameters it includes. However, the RPL model is presented here to ensure the results are comparable across models. bAttribute rescaled so
1% = 10%. cAttribute rescaled so £1 = £100. *P < 005; **P < 001; ***P < 0001.
Table 5 Estimated marginal rates of substitution for willingness to delay treatment
Willingness to delay treatment
Patient organization (n = 67) Online panel provider (n = 145)
For a biologic calculator with attributes and levels
set to be the same as current prescribing (constant)
2562 days (–18928 to 24052) 61168 days (4432 to 117903)
For a £100 saving 325 days (000 to 650) 389 days (050 to 727)
For a 10% increase in PPV 1922 days (641 to 3203) 1409 days (534 to 2284)
For a 10% increase in NPV 2884 days (–728 to 6496) 2295 days (–350 to 4939)
For a 1% decrease in risk of serious infection 723 days (073 to 1372) 1051 days (337 to 1765)
NPV, negative predictive value (ability to predict nonresponse); PPV, positive predictive value (ability to predict response).
© 2021 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists
British Journal of Dermatology (2021)
Patient preferences for stratified medicine in psoriasis, G. Dalal et al. 7
The ability of the algorithm to determine response (PPV)
and nonresponse (NPV) were the two most important attri-
butes driving preferences in both samples relative to the other
attributes in the DCE. However, NPV was not statistically sig-
nificant in the patient organization sample. The next most
influential attribute was the risk of infection. These data on
the trade-offs that patients were willing to make are informa-
tive to researchers involved in the development of prescribing
algorithms to introduce stratified medicine into practice.
Importantly, this study suggested that NPV was as important
as PPV to patients, although it was not statistically significant
in the patient organization sample. This suggests that patients
showed a clear preference to avoid being prescribed a biologi-
cal treatment that will not work for them. This finding is
important as most research aims to identify markers of
response (rather than nonresponse).37,38
The observation that probability of nonresponse was a key
factor driving preferences has been shown in other DCEs. For
example, in a DCE comparing algorithm-based prescribing to
conventional prescribing in RA, the authors reported that NPV
was a predictor of preferences.15 Another DCE that elicited
preferences of neurologists for pharmacogenetic testing in epi-
lepsy also suggested NPV to be a strong predictor of prefer-
ences.39 This suggests that NPV is important not only for
people with psoriasis, but also for physicians and for people
with RA and other autoimmune conditions.
The presence of scale and preference heterogeneity indi-
cated that there were variations in the preferences of the sam-
ples. In such cases, it would be incorrect to form conclusions
from merging the data from both samples and using a pooled
conditional logit model.40 This meant that the estimated coef-
ficients across the two samples should not be directly com-
pared. To overcome this, values for MRS were estimated using
delay to the start of treatment as a value attribute to provide a
way of comparing the observed choices from both samples.
Using this approach provides a solution to overcome the issue
of heterogeneity owing to the simple division of attribute
coefficients to obtain ratios.40,41
The findings of this DCE survey come with limitations. The
use of an online panel provider for patient recruitment could
limit the generalizability of the results to the population of people
with psoriasis likely to be prescribed a biologic. The main moti-
vation behind this source of recruitment was to increase the sam-
ple size and acquire responses in a quick and low-cost manner
when compared with telephone interviews or postal surveys.42
The choice data collected in this study suggested there was
a considerable variation in preferences within and across the
two samples. This finding suggests that there is not a common
MRS for all respondents and the reported MRS should be
viewed with caution.
Further research should aim to recruit a more representative
sample of respondents to capture the preferences of people
likely to be prescribed a biologic, which would allow us to
determine the generalizability of the results of this study. The
preferences of clinicians involved in the prescribing of biolog-
ical therapies could also be investigated and compared with
those of the patients. Further methodological research is
required to assess the impact of nonlinear attributes on esti-
mates of MRS.43
The potential contribution of eliciting patient preferences is
to use these results to inform the subsequent design of a bio-
logic calculator that takes account of the need to achieve ade-
quate levels of, for example, PPV and NPV. Currently, the
types and number of tests to include in a prescribing algo-
rithm are unknown. Future development would involve devel-
oping a prediction algorithm and embedding the biologic
calculator (using the results of tests as an input into a predic-
tion algorithm), informed by known patient and/or genetic
characteristics, into the prescribing pathway of biologics for
people with psoriasis. Therefore, a model of service delivery
will be required to enable clinicians to collect information to
feed into the biologic calculator and inform the patient of the
subsequent treatment choice. Further research, using methods
from implementation science,44,45 should be undertaken to
understand how the biologic calculator could be used in clini-
cal practice.
This study aimed to quantify the preferences of patients for
algorithm-based prescribing (biologic calculator) vs. conven-
tional prescribing of biologics for people with psoriasis. The
results suggested that patients assigned the greatest value to
the ability of the biologic calculator to predict response (PPV)
and nonresponse (NPV), followed by the risk of serious infec-
tion from the biologic. These findings have important implica-
tions for the implementation of stratified medicine in
psoriasis, and suggest that tools should be designed with the
goal of reaching a sufficient level of predictive accuracy given
the cost of implementing these into clinical practice.
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